| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dementia | 15 | 2021 | 452 | 2.470 |
Why?
|
| Medicare | 19 | 2024 | 424 | 2.070 |
Why?
|
| Comparative Effectiveness Research | 5 | 2012 | 68 | 1.410 |
Why?
|
| Hypertension | 10 | 2023 | 1323 | 1.380 |
Why?
|
| Aged | 87 | 2024 | 19764 | 1.310 |
Why?
|
| Retrospective Studies | 69 | 2024 | 16335 | 1.280 |
Why?
|
| United States | 67 | 2024 | 10899 | 1.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 224 | 1.260 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 529 | 1.220 |
Why?
|
| Heart Failure | 17 | 2016 | 2285 | 1.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2022 | 732 | 1.110 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 2511 | 1.100 |
Why?
|
| SEER Program | 3 | 2024 | 202 | 1.020 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2018 | 729 | 1.010 |
Why?
|
| Antipsychotic Agents | 12 | 2021 | 361 | 1.010 |
Why?
|
| Risk | 14 | 2017 | 755 | 0.970 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2023 | 128 | 0.960 |
Why?
|
| United States Department of Veterans Affairs | 10 | 2012 | 672 | 0.950 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 1356 | 0.900 |
Why?
|
| Cholinergic Antagonists | 7 | 2019 | 51 | 0.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2024 | 1270 | 0.900 |
Why?
|
| Prescription Drugs | 5 | 2019 | 54 | 0.860 |
Why?
|
| Antihypertensive Agents | 5 | 2012 | 412 | 0.810 |
Why?
|
| Diabetes Mellitus | 13 | 2023 | 872 | 0.810 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 251 | 0.780 |
Why?
|
| Aged, 80 and over | 33 | 2024 | 6548 | 0.770 |
Why?
|
| Economics, Pharmaceutical | 3 | 2009 | 8 | 0.750 |
Why?
|
| Hospitals, Veterans | 17 | 2007 | 359 | 0.740 |
Why?
|
| Depression | 12 | 2020 | 1223 | 0.730 |
Why?
|
| Databases, Factual | 11 | 2024 | 1178 | 0.730 |
Why?
|
| Comorbidity | 16 | 2020 | 1531 | 0.720 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 352 | 0.700 |
Why?
|
| Female | 85 | 2024 | 66569 | 0.700 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2021 | 28 | 0.700 |
Why?
|
| Metformin | 1 | 2022 | 151 | 0.700 |
Why?
|
| Hyperlipidemias | 4 | 2022 | 176 | 0.700 |
Why?
|
| Cohort Studies | 28 | 2022 | 4806 | 0.660 |
Why?
|
| Selection Bias | 2 | 2009 | 22 | 0.660 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 1952 | 0.650 |
Why?
|
| Humans | 119 | 2024 | 124725 | 0.650 |
Why?
|
| Nursing Homes | 11 | 2019 | 92 | 0.640 |
Why?
|
| Male | 82 | 2024 | 61269 | 0.620 |
Why?
|
| Dyslipidemias | 2 | 2015 | 232 | 0.600 |
Why?
|
| Risk Adjustment | 5 | 2015 | 58 | 0.600 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 209 | 0.570 |
Why?
|
| Risk Assessment | 8 | 2016 | 3447 | 0.570 |
Why?
|
| Motivational Interviewing | 3 | 2023 | 46 | 0.560 |
Why?
|
| Medicare Part C | 5 | 2023 | 38 | 0.560 |
Why?
|
| Medicare Part D | 4 | 2020 | 17 | 0.550 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1659 | 0.530 |
Why?
|
| Epidemiologic Research Design | 1 | 2016 | 4 | 0.530 |
Why?
|
| Paroxetine | 4 | 2017 | 28 | 0.520 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 259 | 0.510 |
Why?
|
| Middle Aged | 50 | 2024 | 26797 | 0.500 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 295 | 0.500 |
Why?
|
| Veterans | 11 | 2011 | 1757 | 0.490 |
Why?
|
| Odds Ratio | 5 | 2016 | 1259 | 0.490 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 514 | 0.470 |
Why?
|
| Multivariate Analysis | 14 | 2016 | 1435 | 0.460 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1328 | 0.450 |
Why?
|
| Drug Utilization Review | 3 | 2019 | 33 | 0.420 |
Why?
|
| Logistic Models | 16 | 2017 | 1812 | 0.410 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 58 | 0.400 |
Why?
|
| Managed Care Programs | 3 | 2022 | 61 | 0.400 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 41 | 0.390 |
Why?
|
| Losartan | 1 | 2011 | 36 | 0.370 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 125 | 0.370 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 56 | 0.370 |
Why?
|
| Valine | 1 | 2011 | 112 | 0.360 |
Why?
|
| Tetrazoles | 1 | 2011 | 68 | 0.360 |
Why?
|
| Pneumonia | 3 | 2020 | 323 | 0.350 |
Why?
|
| Case-Control Studies | 14 | 2023 | 3284 | 0.350 |
Why?
|
| Benzimidazoles | 1 | 2011 | 132 | 0.350 |
Why?
|
| Medication Adherence | 6 | 2023 | 397 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 262 | 0.340 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 10 | 0.330 |
Why?
|
| Quality Indicators, Health Care | 3 | 2019 | 219 | 0.330 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 197 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1214 | 0.330 |
Why?
|
| Risk Factors | 23 | 2017 | 10286 | 0.320 |
Why?
|
| Survival Rate | 5 | 2023 | 2047 | 0.320 |
Why?
|
| Angioplasty | 2 | 2007 | 89 | 0.320 |
Why?
|
| Incidence | 15 | 2019 | 3142 | 0.310 |
Why?
|
| Pharmaceutical Services | 1 | 2009 | 35 | 0.310 |
Why?
|
| Multiple Sclerosis | 2 | 2023 | 329 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 4 | 2011 | 231 | 0.310 |
Why?
|
| Propensity Score | 7 | 2017 | 216 | 0.300 |
Why?
|
| Aortic Aneurysm, Abdominal | 4 | 2007 | 449 | 0.300 |
Why?
|
| Baths | 2 | 2020 | 16 | 0.300 |
Why?
|
| Elective Surgical Procedures | 3 | 2007 | 160 | 0.300 |
Why?
|
| Research | 3 | 2023 | 263 | 0.300 |
Why?
|
| Health Expenditures | 3 | 2018 | 102 | 0.290 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2020 | 71 | 0.290 |
Why?
|
| Accidental Falls | 3 | 2016 | 104 | 0.280 |
Why?
|
| Neoplasms | 2 | 2020 | 2788 | 0.280 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2017 | 7 | 0.280 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 431 | 0.280 |
Why?
|
| Diuretics | 2 | 2005 | 171 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 307 | 0.280 |
Why?
|
| Drug Utilization | 3 | 2020 | 160 | 0.280 |
Why?
|
| Treatment Outcome | 12 | 2023 | 12356 | 0.270 |
Why?
|
| Leptospirosis | 1 | 2006 | 5 | 0.270 |
Why?
|
| Quality of Health Care | 5 | 2005 | 390 | 0.270 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2022 | 100 | 0.270 |
Why?
|
| Fractures, Bone | 3 | 2016 | 186 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 258 | 0.270 |
Why?
|
| Dog Diseases | 1 | 2006 | 50 | 0.260 |
Why?
|
| Data Collection | 3 | 2016 | 381 | 0.260 |
Why?
|
| Varenicline | 2 | 2016 | 14 | 0.250 |
Why?
|
| Bupropion | 2 | 2016 | 28 | 0.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2016 | 36 | 0.250 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 417 | 0.250 |
Why?
|
| Hospitalization | 10 | 2012 | 1779 | 0.240 |
Why?
|
| Ethical Review | 1 | 2005 | 3 | 0.240 |
Why?
|
| Inappropriate Prescribing | 2 | 2015 | 41 | 0.240 |
Why?
|
| Adult | 29 | 2024 | 29488 | 0.240 |
Why?
|
| Cross Infection | 2 | 2020 | 323 | 0.240 |
Why?
|
| Ethics Committees, Research | 1 | 2005 | 32 | 0.240 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 66 | 0.240 |
Why?
|
| Alzheimer Disease | 3 | 2022 | 795 | 0.240 |
Why?
|
| Human Experimentation | 1 | 2005 | 36 | 0.240 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 25 | 0.230 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2023 | 33 | 0.230 |
Why?
|
| Obesity | 2 | 2015 | 2245 | 0.230 |
Why?
|
| Internationality | 3 | 2009 | 131 | 0.230 |
Why?
|
| Outpatients | 1 | 2006 | 252 | 0.230 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 221 | 0.230 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 238 | 0.230 |
Why?
|
| Methadone | 1 | 2024 | 126 | 0.220 |
Why?
|
| Polypharmacy | 3 | 2019 | 40 | 0.220 |
Why?
|
| Smoking Cessation | 2 | 2016 | 198 | 0.220 |
Why?
|
| Homes for the Aged | 4 | 2017 | 24 | 0.220 |
Why?
|
| Focus Groups | 1 | 2024 | 198 | 0.220 |
Why?
|
| Workload | 1 | 2005 | 145 | 0.220 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 443 | 0.220 |
Why?
|
| Psychotic Disorders | 3 | 2010 | 135 | 0.210 |
Why?
|
| Decision Making | 4 | 2009 | 655 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 41 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 818 | 0.200 |
Why?
|
| Parkinson Disease | 2 | 2020 | 693 | 0.200 |
Why?
|
| Benzodiazepines | 4 | 2017 | 98 | 0.200 |
Why?
|
| Drug Therapy, Combination | 5 | 2024 | 1163 | 0.200 |
Why?
|
| Surgery Department, Hospital | 1 | 2002 | 19 | 0.190 |
Why?
|
| Postmenopause | 1 | 2022 | 126 | 0.190 |
Why?
|
| Cross-Sectional Studies | 9 | 2020 | 3432 | 0.190 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 260 | 0.190 |
Why?
|
| Biological Products | 1 | 2023 | 121 | 0.190 |
Why?
|
| Medication Errors | 2 | 2015 | 186 | 0.190 |
Why?
|
| Medicaid | 4 | 2024 | 242 | 0.190 |
Why?
|
| Hospital Mortality | 3 | 2015 | 1027 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1037 | 0.180 |
Why?
|
| Health Status | 3 | 2016 | 375 | 0.180 |
Why?
|
| Cognition | 2 | 2015 | 722 | 0.180 |
Why?
|
| Muscarinic Antagonists | 4 | 2021 | 37 | 0.180 |
Why?
|
| Depressive Disorder | 3 | 2015 | 450 | 0.180 |
Why?
|
| Intensive Care Units | 4 | 2020 | 490 | 0.170 |
Why?
|
| Chlorhexidine | 2 | 2020 | 45 | 0.170 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 292 | 0.170 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 22 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2003 | 371 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2016 | 1189 | 0.160 |
Why?
|
| Psychotropic Drugs | 2 | 2019 | 120 | 0.160 |
Why?
|
| Electronic Health Records | 2 | 2020 | 723 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 607 | 0.160 |
Why?
|
| Advisory Committees | 2 | 2011 | 153 | 0.160 |
Why?
|
| Lipids | 1 | 2022 | 514 | 0.160 |
Why?
|
| Patient Readmission | 4 | 2016 | 385 | 0.160 |
Why?
|
| Deprescriptions | 1 | 2019 | 12 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2015 | 471 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 48 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 57 | 0.150 |
Why?
|
| Drug Industry | 1 | 2018 | 46 | 0.150 |
Why?
|
| Drug Interactions | 1 | 2019 | 254 | 0.150 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 517 | 0.150 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 148 | 0.150 |
Why?
|
| Texas | 7 | 2023 | 3585 | 0.150 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 5 | 0.140 |
Why?
|
| Diabetes Complications | 4 | 2010 | 202 | 0.140 |
Why?
|
| Health Services Research | 3 | 2002 | 188 | 0.140 |
Why?
|
| Drug Costs | 1 | 2018 | 61 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 172 | 0.140 |
Why?
|
| Controlled Substances | 1 | 2017 | 12 | 0.140 |
Why?
|
| Health Policy | 2 | 2009 | 212 | 0.140 |
Why?
|
| Patient Discharge | 4 | 2016 | 490 | 0.140 |
Why?
|
| Prospective Studies | 9 | 2019 | 6147 | 0.140 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 10 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
| Age Factors | 6 | 2015 | 2820 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2009 | 778 | 0.130 |
Why?
|
| Critical Care | 2 | 2020 | 657 | 0.130 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 34 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2428 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 45 | 0.120 |
Why?
|
| Hip Fractures | 1 | 2016 | 61 | 0.120 |
Why?
|
| Southeastern United States | 2 | 2006 | 36 | 0.120 |
Why?
|
| Palliative Care | 1 | 2019 | 428 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 89 | 0.120 |
Why?
|
| Physicians | 2 | 2019 | 581 | 0.120 |
Why?
|
| Health Services Administration | 2 | 2005 | 11 | 0.120 |
Why?
|
| Diagnosis-Related Groups | 1 | 1995 | 28 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 372 | 0.120 |
Why?
|
| Hospital Information Systems | 1 | 1995 | 44 | 0.120 |
Why?
|
| Residence Characteristics | 3 | 2012 | 278 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 1089 | 0.120 |
Why?
|
| Methotrexate | 3 | 2023 | 341 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 174 | 0.120 |
Why?
|
| Colistin | 1 | 2014 | 30 | 0.110 |
Why?
|
| Research Design | 2 | 2011 | 693 | 0.110 |
Why?
|
| Causality | 2 | 2015 | 83 | 0.110 |
Why?
|
| Lung Diseases, Obstructive | 7 | 1999 | 34 | 0.110 |
Why?
|
| Health Personnel | 1 | 2019 | 505 | 0.110 |
Why?
|
| Prevalence | 5 | 2017 | 2447 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 127 | 0.110 |
Why?
|
| Health Resources | 1 | 1995 | 116 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 87 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 242 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 634 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2015 | 870 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2012 | 287 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 238 | 0.110 |
Why?
|
| Mental Disorders | 2 | 2019 | 820 | 0.110 |
Why?
|
| Anxiety Disorders | 2 | 2009 | 672 | 0.100 |
Why?
|
| Dementia, Vascular | 2 | 2010 | 17 | 0.100 |
Why?
|
| Weight Gain | 1 | 2016 | 403 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 453 | 0.100 |
Why?
|
| Observation | 2 | 2010 | 42 | 0.100 |
Why?
|
| HIV Seroprevalence | 1 | 1992 | 9 | 0.100 |
Why?
|
| California | 3 | 2006 | 128 | 0.100 |
Why?
|
| Sterilization, Tubal | 1 | 1992 | 12 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1102 | 0.100 |
Why?
|
| Housing | 1 | 2012 | 59 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 102 | 0.100 |
Why?
|
| Galantamine | 2 | 2022 | 10 | 0.100 |
Why?
|
| Rivastigmine | 2 | 2022 | 17 | 0.100 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 51 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 3 | 2007 | 206 | 0.100 |
Why?
|
| Sex Factors | 2 | 2015 | 1287 | 0.100 |
Why?
|
| Hospitals | 1 | 1995 | 389 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 224 | 0.100 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 15 | 0.100 |
Why?
|
| Drug Therapy | 2 | 2010 | 87 | 0.090 |
Why?
|
| Models, Structural | 1 | 2011 | 50 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 2877 | 0.090 |
Why?
|
| Valsartan | 1 | 2011 | 26 | 0.090 |
Why?
|
| Fosinopril | 1 | 2011 | 5 | 0.090 |
Why?
|
| Adolescent | 11 | 2023 | 19284 | 0.090 |
Why?
|
| Lisinopril | 1 | 2011 | 25 | 0.090 |
Why?
|
| Enalapril | 1 | 2011 | 18 | 0.090 |
Why?
|
| Captopril | 1 | 2011 | 28 | 0.090 |
Why?
|
| Indans | 2 | 2022 | 55 | 0.090 |
Why?
|
| Medication Systems, Hospital | 1 | 2011 | 42 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1662 | 0.090 |
Why?
|
| Leg | 2 | 2002 | 158 | 0.090 |
Why?
|
| Nurses | 1 | 2011 | 64 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 114 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2156 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5161 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 164 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 1046 | 0.080 |
Why?
|
| Piperidines | 2 | 2022 | 204 | 0.080 |
Why?
|
| Young Adult | 6 | 2024 | 9023 | 0.080 |
Why?
|
| Fee-for-Service Plans | 1 | 2009 | 18 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 122 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 110 | 0.080 |
Why?
|
| Poverty | 1 | 1992 | 422 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 2 | 2007 | 577 | 0.080 |
Why?
|
| Sick Role | 1 | 2009 | 31 | 0.080 |
Why?
|
| Somatoform Disorders | 1 | 2009 | 46 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2010 | 249 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2021 | 680 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2009 | 122 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 649 | 0.070 |
Why?
|
| ROC Curve | 1 | 2009 | 570 | 0.070 |
Why?
|
| Kidney | 1 | 2014 | 1358 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 408 | 0.070 |
Why?
|
| Iatrogenic Disease | 2 | 1999 | 133 | 0.070 |
Why?
|
| Quetiapine Fumarate | 3 | 2012 | 16 | 0.070 |
Why?
|
| Demography | 2 | 2006 | 240 | 0.070 |
Why?
|
| Dibenzothiazepines | 3 | 2012 | 14 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2009 | 1499 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 546 | 0.070 |
Why?
|
| Quality of Life | 1 | 2016 | 1935 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2009 | 387 | 0.070 |
Why?
|
| Risperidone | 3 | 2012 | 59 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 61 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 340 | 0.060 |
Why?
|
| Environment | 1 | 2006 | 145 | 0.060 |
Why?
|
| Time Factors | 5 | 2016 | 6308 | 0.060 |
Why?
|
| Dogs | 1 | 2006 | 768 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 596 | 0.060 |
Why?
|
| Oklahoma | 1 | 2004 | 8 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 256 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 307 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 1111 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 133 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 607 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 166 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 180 | 0.060 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 109 | 0.060 |
Why?
|
| Buprenorphine | 1 | 2024 | 95 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2005 | 374 | 0.050 |
Why?
|
| Crotonates | 1 | 2023 | 6 | 0.050 |
Why?
|
| Dimethyl Fumarate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Potassium Deficiency | 1 | 2003 | 12 | 0.050 |
Why?
|
| Netherlands | 1 | 2003 | 38 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 574 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 184 | 0.050 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2011 | 665 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2005 | 350 | 0.050 |
Why?
|
| Policy Making | 1 | 2003 | 58 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2009 | 771 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 2003 | 74 | 0.050 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 3 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2024 | 542 | 0.050 |
Why?
|
| Linear Models | 3 | 2016 | 676 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 351 | 0.050 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 24 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2002 | 134 | 0.040 |
Why?
|
| Benchmarking | 1 | 2002 | 134 | 0.040 |
Why?
|
| Injections | 1 | 2021 | 154 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 2982 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2023 | 381 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 18 | 0.040 |
Why?
|
| HIV Infections | 1 | 1992 | 1891 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2024 | 1136 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 44 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 2895 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 509 | 0.040 |
Why?
|
| Soaps | 1 | 2020 | 8 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 931 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2001 | 168 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2011 | 1016 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2019 | 24 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 110 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 569 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 1313 | 0.040 |
Why?
|
| Students, Pharmacy | 1 | 2019 | 64 | 0.040 |
Why?
|
| Gift Giving | 1 | 2018 | 18 | 0.040 |
Why?
|
| Motivation | 2 | 2018 | 316 | 0.040 |
Why?
|
| Length of Stay | 3 | 2006 | 1312 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2018 | 67 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 444 | 0.040 |
Why?
|
| Pain Management | 1 | 2019 | 181 | 0.040 |
Why?
|
| Isocoumarins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 286 | 0.030 |
Why?
|
| Coumarins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2010 | 806 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 192 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 852 | 0.030 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 41 | 0.030 |
Why?
|
| Disease | 1 | 1997 | 129 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 235 | 0.030 |
Why?
|
| Infection Control | 1 | 2016 | 155 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 113 | 0.030 |
Why?
|
| Health Services | 1 | 1995 | 71 | 0.030 |
Why?
|
| Behavior | 1 | 2015 | 74 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 128 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 127 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 1995 | 103 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 122 | 0.030 |
Why?
|
| Bias | 1 | 1995 | 131 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1995 | 138 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 68 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 260 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 276 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1995 | 181 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 236 | 0.030 |
Why?
|
| Disease Progression | 2 | 2010 | 2049 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 1434 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 134 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2006 | 590 | 0.030 |
Why?
|
| Levonorgestrel | 1 | 1992 | 20 | 0.030 |
Why?
|
| Family Planning Services | 1 | 1992 | 37 | 0.030 |
Why?
|
| APACHE | 3 | 1999 | 53 | 0.020 |
Why?
|
| Attitude | 1 | 1992 | 115 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 21 | 0.020 |
Why?
|
| Prognosis | 2 | 2011 | 4627 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1995 | 674 | 0.020 |
Why?
|
| Workflow | 1 | 2011 | 118 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 8 | 0.020 |
Why?
|
| Patient Care | 1 | 2011 | 99 | 0.020 |
Why?
|
| Pulmonary Medicine | 1 | 2010 | 24 | 0.020 |
Why?
|
| Utilization Review | 1 | 2009 | 40 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2009 | 26 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3716 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 1995 | 790 | 0.020 |
Why?
|
| Asthma | 1 | 2016 | 749 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 285 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 303 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 591 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 24 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 415 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 437 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 679 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 711 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 721 | 0.020 |
Why?
|
| Child | 2 | 2019 | 24383 | 0.020 |
Why?
|
| Observer Variation | 2 | 1999 | 299 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 924 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8191 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 34024 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1688 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2005 | 110 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2009 | 541 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2008 | 300 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1090 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2009 | 366 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2006 | 201 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 12475 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1883 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 695 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 14018 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 782 | 0.010 |
Why?
|
| Potassium | 1 | 2003 | 280 | 0.010 |
Why?
|
| Total Quality Management | 1 | 2001 | 24 | 0.010 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 58 | 0.010 |
Why?
|
| Anxiety | 1 | 2008 | 941 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 402 | 0.010 |
Why?
|
| Southwestern United States | 1 | 1999 | 43 | 0.010 |
Why?
|
| Medical History Taking | 1 | 1999 | 108 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1269 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 429 | 0.010 |
Why?
|
| Medical Audit | 1 | 1997 | 102 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 1995 | 1 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 31 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 879 | 0.010 |
Why?
|
| Medically Uninsured | 1 | 1995 | 73 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1995 | 67 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 3071 | 0.010 |
Why?
|
| Program Development | 1 | 1994 | 186 | 0.010 |
Why?
|
| Delphi Technique | 1 | 1994 | 214 | 0.010 |
Why?
|
| Drug Implants | 1 | 1992 | 42 | 0.010 |
Why?
|
| Condoms | 1 | 1992 | 49 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1992 | 110 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 2050 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1994 | 541 | 0.010 |
Why?
|